Resources
Videos
Bacterial contamination of platelet components, passive vs. active, surveillance, testing and pathogen reduction technologies
Stanford Blood Center – the first blood center of its size to implement pathogen reduction for 100% of platelet components
Experiences of standardized volume, pathogen-reduced, pooled plasma for faster availability of components for transfusion
Overview of the variability in platelet production processes and applied safety measures
Case study: impact of pathogen inactivation on outdating rates and supply continuity
Case study: enabling double dose methodology on Reveos through pathogen inactivation
Cryoprecipitate from pathogen reduced concurrent apheresis plasma
Production and in vitro quality of pooled whole blood derived PI plasma
Production and in vitro quality of pooled whole blood derived PI plasma
How pools-of-pools contributes to optimising your PI platelet products
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products Using the INTERCEPT Blood System
How to bring bacterial risk control strategies within financial reach
No results found.